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CCL23, also known as myeloid progenitor inhibitory factor (MPIF)-1, macrophage
inflammatory protein (MIP)-3, or CKβ8, is a member of the CC chemokine subfamily
exerting its effects via CCR1 binding. By doing so, CCL23 selectively recruits resting
T lymphocytes and monocytes, inhibits proliferation of myeloid progenitor cells and
promotes angiogenesis. Previously, we and other groups have reported that human
neutrophils are able to produce chemokines upon appropriate activation, including
CCR1-binding CCL2, CCL3, and CCL4. Herein, we demonstrate that human neutrophils
display the capacity to also express and release CCL23 when stimulated by R848
and, to a lesser extent, by other pro-inflammatory agonists, including LPS, Pam3CSK4,
and TNFα. Notably, we show that, on a per cell basis, R848-activated neutrophils
produce higher levels of CCL23 than autologous CD14+-monocytes activated under
similar experimental conditions. By contrast, we found that, unlike CD14+-monocytes,
neutrophils do not produce CCL23 in response to IL-4, thus indicating that they express
CCL23 in a stimulus-specific fashion. Finally, we show that the production of CCL23 by
R848-stimulated neutrophils is negatively modulated by IFNα, which instead enhances
that of CCL2. Together, data extend our knowledge on the chemokines potentially
produced by neutrophils. The ability of human neutrophils to produce CCL23 further
supports the notion on the neutrophil capacity of orchestrating the recruitment of different
cell types to the inflamed sites, in turn contributing to the control of the immune response.
Keywords: neutrophils, CCL23, R848, CCR1, IFN
INTRODUCTION
Neutrophils are known to perform a series of effector functions, including phagocytosis,
discharge of constitutively stored proinflammatory molecules, generation of massive amounts
of superoxide anion, and active release of neutrophil extracellular traps (NETs), that are all
crucial for innate immunity responses toward infections (Scapini et al., 2013). In addition to
their defensive functions, neutrophils display the capacity to synthesize and secrete a variety of
cytokines, including many chemokines (Tecchio and Cassatella, 2016). For instance, depending
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on the stimulatory conditions, human neutrophils have been
shown to produce both CXC chemokines, such as CXCL1
(GROα), CXCL3, CXCL5 (ENA78), CXCL6, CXCL8 (IL-8),
CXCL9 (MIG), CXCL10 (IP-10), CXCL11 (I-TAC), and CC
chemokines, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL4
(MIP-1β), CCL17, CCL18, CCL19 (MIP-3β), and CCL20 (MIP-
3α) (reviewed by Tecchio and Cassatella, 2016). Given that these
chemokines recruit leukocytes associated to either the innate
[including neutrophils themselves, monocytes, macrophages,
dendritic cells (DCs), and natural killer (NK) cells] or the
acquired (such as T cell subsets) immune responses (Viola and
Luster, 2008; Griffith et al., 2014), it is plausible to speculate
that neutrophils are in the position to orchestrate leukocyte
trafficking during the entire course of specific responses to
invading pathogens or other antigens (Tecchio and Cassatella,
2016).
In this context, CCL23, also known as myeloid progenitor
inhibitory factor (MPIF)-1, macrophage inflammatory protein
(MIP)-3, or CKβ8, is a recently identified CCL, which, similarly to
CCL3, CCL5, CCL7, CCL13, CCL14, CCL15, and CCL16, binds
CCR1 (Youn et al., 1998; Viola and Luster, 2008). Also CCL4 and
CCL2 have been shown to bind CCR1: the former one, however,
after natural truncation of its two NH2-terminal amino acids
(Guan et al., 2002), the latter one with lower affinity as compared
to its binding to CCR2 (Menten et al., 2002). Similarly to other
CCR1 binding chemokines, CCL23 exerts chemotactic activities
on monocytes, DCs and resting T lymphocytes (Patel et al., 1997;
Youn et al., 1998; Nardelli et al., 1999), as well as on endothelial
cells to ultimately induce tube formation (Hwang et al., 2005;
Son et al., 2006). Moreover, CCL23 has been reported to play a
role in bone formation, for its potent chemoattractant action on
osteoclast precursors, but not for fully differentiated osteoclasts
or osteoblasts (Votta et al., 2000). Amore precise characterization
of CCL23 function is however hindered by the fact that CCL23 is
a gene with no mouse ortholog (Viola and Luster, 2008), which
thus prevents the employment of loss-of-function strategies
in experimental animal models. While CCL23/MPIF-1 cDNA
was originally isolated from a human aortic endothelial library
(Patel et al., 1997), subsequent analysis made on various cell
lines has shown that CCL23 mRNA is readily detectable in
myelomonocytic cell lines (Patel et al., 1997). Expression of
CCL23 mRNA was then found in monocytes stimulated with
IL-1β (Forssmann et al., 1997) and it is now established that
IL-4-treated monocytes produce remarkable amounts of CCL23
(Nardelli et al., 1999; Novak et al., 2007). CCL23 can be detected
in synovial fluids from rheumatoid arthritis patients (Berahovich
et al., 2005), as well as in serum of systemic sclerosis patients
(Yanaba et al., 2011). More recently, eosinophils freshly isolated
from blood were found to express CCL23 mRNA and, in turn,
secrete antigenic CCL23 upon incubation with IL-5 or GM-CSF
(Matsumoto et al., 2011).
Since no information was present in the literature on an
eventual expression/production of CCL23 by neutrophils, we
decided to investigate such a possibility. As a result, we herein
show that also human neutrophils produce CCL23 in vitro, yet
upon incubation with selected stimuli and in a fashion regulated
by endogenous TNFα and exogenous IFNα.
MATERIALS AND METHODS
Cell Purification and Culture
Granulocytes and autologous CD14+-monocytes were isolated
from buffy coats of healthy donors, under endotoxin-free
conditions as previously described (Davey et al., 2011). Briefly,
buffy coats were stratified on Ficoll-Paque PLUS gradient (GE
Healthcare, Little Chalfont, United Kingdom) at a 1:1 ratio, and
then centrifuged at 400 × g for 30min at room T. Granulocytes
were then collected and subjected to dextran sedimentation
followed by hypotonic lysis to remove erythrocytes. Finally,
neutrophils were isolated from granulocytes (to reach a
99.7 ± 0.2% purity) by positively removing all contaminating
cells using the EasySep neutrophil enrichment kit (StemCell
Technologies, Vancouver, Canada; Calzetti et al., 2017). CD14+-
monocytes were instead isolated from PBMCs, obtained after
Ficoll-Paque gradient centrifugation, by anti-CD14 microbeads
(Miltenyi Biotec, Bergisch Gladbach, Germany) to reach a
purity of ∼98%. Cells were then suspended at 5 × 106/ml in
RPMI 1640 medium supplemented with 10% low endotoxin
FBS (<0.5 EU/ml; from BioWhittaker-Lonza, Basel, Switzerland)
and then plated either in 6/24-well tissue culture plates or
in polystyrene flasks (from Greiner Bio-One, Kremsmünster,
Austria) for culture at 37◦C, 5% CO2 atmosphere, in the
presence or the absence of: 0.2–50µM R848, 5–50µM R837,
1µg/ml Pam3CSK4 (Invivogen, San Diego, CA, USA), 10 ng/ml
TNFα (Peprotech, Rocky Hill, NJ, USA), 0.1–10µg/ml ultrapure
LPS from E. coli 0111:B4 strain (Alexis, Enzo Life Sciences,
Farmingdale, NY, USA), 1,000U/ml pegylated IFNα-2a (Pegasys,
Roche, Basel, Switzerland), 100 U/ml IFNγ (R&D Systems,
Minneapolis, MN, USA), 10 ng/ml GM-CSF (Miltenyi Biotec),
1,000 U/ml G-CSF (Myelostim, Italfarmaco Spa, Milano, Italy),
10–100 ng/ml IL-18 (MBL International, Nagoya, Japan), 10–
100 ng/ml IL-33 (Peprotech), 10 nM fMLF (Sigma, Saint Louis,
MO, USA), 500µg/ml particulate β-glucan (InvivoGen), or
500µg/ml curdlan (Sigma). In some experiments, neutrophils
were preincubated for 30min with either 10 µg/ml adalimumab
(Humira, Abbott Biotechnology Limited, Barceloneta, Puerto
Rico) or 10µg/ml etanercept (Enbrel, Amgen, Thousand Oaks,
CA, USA), prior to further incubation with stimuli. After
the desired incubation period, neutrophils and monocytes
were collected and spun at 300 × g for 5min. Cell-free
supernatants were immediately frozen in liquid nitrogen
and stored at −80 ◦C, while the corresponding cell pellets
were either extracted for total RNA or lysed for protein
analysis.
ELISA
Cytokine concentrations in cell-free supernatants and cell-
lysates were measured by commercially available ELISA
kits, specific for human: CXCL8 (Mabtech, Nacka Strand,
Sweden), CCL23 (R&D Systems, Minneapolis, MN, USA),
CCL2 (R&D Systems), CCL3 (eBioscience, San Diego, CA,
USA), and CCL4 (eBioscience). Detection limits of these
ELISA were: 7.8 pg/ml for CCL23, 7.8 pg/ml for CCL2,
16 pg/ml for CCL3, 4 pg/ml for CCL4, and 16 pg/ml for
CXCL8.
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Reverse Transcription Quantitative
Real-Time PCR (RT-qPCR)
Total RNA was extracted from neutrophils and monocytes by
the RNeasy Mini Kit (Qiagen, Venlo, Limburg, Netherlands),
according to the manufacturer’s instructions. An on-column
DNase digestion with the RNase-free DNase set (Qiagen) was
also performed during total RNA isolation to completely remove
any possible contaminating DNA. Purified total RNA was
then reverse-transcribed into cDNA using Superscript III (Life
Technologies) and random hexamer primers (Life Technologies),
while qPCR was carried out using Fast SYBR R© GreenMasterMix
(Life Technologies) (Tamassia et al., 2014). Sequences of the gene-
specific primers (Life Technologies) used in this study are the
following: GAPDH, forward AACAGCCTCAAGATCATCAGC
and reverse GGATGATGTTCTGGAGAGCC; CXCL8 forward
CTGGCCGTGGCTCTCTTG and reverse CCTTGGCAAAAC
TGCACCTT; IL-1ra forward TTCCTGTTCCATTCAGAGACG
AT and reverse AATTGACATTTGGTCCTTGCAA; CCL2
forward GTCTCTGCCGCCCTTCTGT and reverse TTGCAT
CTGGCTGAGCGAG; CCL3 forward AGCCCACATTCCGTC
ACCTG and reverse CGTGTCAGCAGCAAGTGATG; CCL4
forward CGCCTGCTGCTTTTCTTACAC and reverse CAG
ACTTGCTTGCTTCTTTTGG; and CCL23 forward GTACTT
CTGGACATGCTCTGG and reverse CTGAACTTGCTTATC
ACTGGG. Data were calculated by Q-Gene software (http://
www.gene-quantification.de/download.html) and expressed as
mean normalized expression (MNE) units after GAPDH
normalization.
RNA Sequencing (RNA-seq)
Total RNA extracted from neutrophils (50 × 106/condition)
was quality checked by Agilent 2100 Bioanalyzer (Agilent
Technologies). RNA integrity (RIN) was routinely found to
be ≥7.0. RNA-seq libraries were prepared by oligo-dT selection
using the TruSeq RNA sample preparation kit (Illumina,
San Diego, CA, USA) and sequenced on an Illumina HiSeq
2000. After quality filtering according to the Illumina pipeline,
FIGURE 1 | Expression of CCR1-binding chemokine mRNAs in human
neutrophils incubated with R848. Human neutrophils were incubated with
or without 5µM R848 for 24 h, and then total RNA was extracted and
processed for RNA-seq experiments. Data are presented as FPKM (fragment
per kilobase of exons per million fragments mapped) from two independent
experiments (mean ± SEM).
51-base-pair (bp) reads were aligned to the hg19 assembly
(Genome Reference Consortium GRCh37) as well as the human
transcriptome reference (UCSC annotation), using TopHat
(Trapnell et al., 2013). We allowed up to two mismatches and
specified a mean distance between pairs (–r) of 250 bp. The
reference sequence and annotation files were downloaded from
iGenomes repository at the following website: http://support.
illumina.com/sequencing/sequencing_software/igenome.html.
Read counts per gene were obtained from the aligned reads using
“htseq-count” command from the HTSeq framework version
FIGURE 2 | Kinetics of CCL23, CCL2, CCL3, and CCL4 mRNA
expression in neutrophils and autologousCD14+-monocytes incubated
with R848. Neutrophils and autologous CD14+-monocytes were cultured
with or without 5µM R848 for up to 24 h to evaluate their CCL23 (A), CCL2
(B), CCL3 (C), and CCL4 (D) mRNA expression by RT-qPCR. Gene
expression is depicted as mean normalized expression (MNE) units after
GAPDH mRNA normalization (mean ± SEM, n = 5). Asterisks stand for
significant increase: *P < 0.05, **P < 0.01, ***P < 0.001, by two-way ANOVA
followed by Bonferroni’s post-test.
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0.6.1p1 (Anders et al., 2015), with the following parameters:
“–f bam –r name –m union –s no –t exon –i gene id”. Count
normalization was performed using the Bioconductor/R
packages DESeq2 (Love et al., 2014). Transcript abundance
was indicated as Fragments Per Kilobase of transcript sequence
per Million of mapped fragments (FPKM), using the “fpkm”
function of DESeq2.
Statistical Analysis
Data are expressed as mean ± SEM. Statistical evaluation was
performed by the Student’s t-test, one-way ANOVA followed
by Tukey’s post-hoc test or two-way ANOVA followed by
Bonferroni’s post-hoc test. Values of p < 0.05 were considered as
statistically significant.
Study Approval
This study was carried out in accordance with the
recommendations of “Ethic Committee of the Azienda
Ospedaliera Universitaria Integrata di Verona (Italy)” with
written informed consent from all subjects. All subjects gave
written informed consent in accordance with the Declaration of
Helsinki.
RESULTS
Human Neutrophils Incubated with R848
Accumulate CCL23 Transcripts
We have recently reported that R848 represents a very
powerful inducer of IL-6, TNFα, G-CSF, IL-12-p40, and CXCL8
production by human neutrophils (Zimmermann et al., 2015,
2016). We recall here that R848 is an imidazoquinoline
compound that potently activates the signaling of both TLR7 and
TLR8 (Jurk et al., 2002), but that in human neutrophils activates
only TLR8 (Janke et al., 2009; Zimmermann et al., 2015) as these
cells do not express TLR7 (Hayashi et al., 2003; Janke et al., 2009;
Berger et al., 2012; Zimmermann et al., 2015). Moreover, results
from RNA-seq experiments to discover unidentified molecules
eventually generated by human neutrophils incubated for 24
h with 5µM R848 indicated that, among the various CCR1-
binding chemokines (Griffith et al., 2014), neutrophils express
the mRNA for CCL2, CCL3, CCL4, and CCL23, but not CCL5,
CCL7, CCL8, CCL13, CCL14, CCL15, and CCL16 (Figure 1).
Figure 1 further shows that, in R848-stimulated neutrophils, the
levels of CCL3 and CCL4 mRNAs are remarkably higher than
those of CCL2 and CCL23 mRNAs. While neutrophil expression
of CCL2, CCL3, and CCL4 mRNA is well-established (Kasama
et al., 1993, 1994; Cassatella, 1999; Yamashiro et al., 1999), that of
CCL23 has been never described before.
To validate and extend these preliminary findings,
neutrophils, as well as autologous CD14+-monocytes, incubated
with R848 were subjected to RT-qPCR experiments in which the
kinetics of CCL23, CCL2, CCL3, and CCL4 mRNA expression
were compared. As shown in Figure 2, CCL23 mRNA expression
in neutrophils started to be detected after 3 h, peaked at the
12 h-time point and slowly declined thereafter (Figure 2A, left
panel). Similarly to CCL23, also CCL2 mRNA started to be
accumulated in neutrophils later than 3 h, but then steadily
increased up to 24 h (Figure 2B, left panel). By contrast, CCL3
and CCL4 mRNAs were induced by R848 as early as after 1 h, but
then followed a time-course pattern similar to CCL23 mRNA
(Figures 2C,D, left panels). Interestingly, maximum expression
levels of both CCL23 and CCL2 mRNAs in R848-treated
neutrophils were similar (Figures 2A,B, left panels), but much
lower than those of CCL3 and CCL4 mRNAs (Figures 2C,D, left
panels). Notably, expression levels, as well as kinetics of CCL23
(Figure 2A, right panel), CCL2 (Figure 2B, right panel), CCL3
(Figure 2C, right panel), and CCL4 (Figure 2D, right panel)
mRNAs in R848-treated monocytes strikingly differed from
those in neutrophils. For instance, the peak of CCL2, CCL3,
and CCL4 mRNA expression in R848-treated monocytes was
found to occur earlier than in neutrophils (Figures 2B,C), unlike
that of CCL23 mRNA, which was found to take place later,
consistent with the increase of CCL23 transcripts starting not
before 12 h of incubation (Figure 2A). Moreover, while CCL2
and CCL3 mRNAs accumulated in R848-treated monocytes at
higher levels than in neutrophils (Figures 2B,C), the opposite
was observed in the case of CCL23 and CCL4 transcripts
(Figures 2A,D). Altogether, data demonstrate that neutrophils
incubated with R848 genuinely express CCL23 mRNA, yet in
a different fashion as compared to CCL2, CCL3, and CCL4
FIGURE 3 | Production of CCL23 by neutrophils and monocytes incubated with R848. Neutrophils and CD14+-monocytes were cultured at 5 × 106 cells/ml
with or without 5µM R848 for up to 48 h to evaluate their capacity to produce and release CCL23, as detected by ELISA (n = 4–19) (A). In (B), neutrophils were
cultured with or without 5µM R848 for 24 h and then further incubated for 4 h with or without 10 nM fMLF or 10 ng/ml TNFα to evaluate released and cell-associated
CCL23 (n = 4). Asterisks stand for significant increases: ***P < 0.001 by two-way ANOVA followed by Bonferroni’s post-test.
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genes, or to CCL23 mRNA expression induced in autologous
monocytes.
Human Neutrophils Incubated with R848
Produce Discrete Levels of CCL23
Next, we analyzed whether R848-treated neutrophils are able
to synthesize and release CCL23 and found that they actually
do so. CCL23 protein was, in fact, detected in neutrophil-
derived supernatants, but starting only after 12 h of cell
incubation with R848, and with peak levels reached after 24 h
(211.1 ± 34.2, n = 4–13) (Figure 3A, left panel). This is
consistent with the delayed induction of CCL23 mRNA by
FIGURE 4 | Effect of IL-4 on the production of CCL23 by monocytes
and neutrophils. CD14+-monocytes and neutrophils were cultured at 5 ×
106 cells/ml with or without 20 ng/ml IL-4 for 24 and 48 h to evaluate their
CCL23 (A) and IL-1ra (B) mRNA expression by RT-qPCR, as well as their
CCL23 release (C) by ELISA (n = 4). Gene expression data are depicted as
MNE units after GAPDH mRNA normalization (mean ± SEM). Asterisks stand
for significant increases: *P < 0.05, ***P < 0.001 by two-way ANOVA followed
by Bonferroni’s post-test.
R848, which, by the way, is also known to prolong neutrophil
survival (Zimmermann et al., 2016). Moreover, previous dose-
response experiments revealed that 5µM R848 correspond to
the most effective concentrations to induce the production of
CCL23 (data not shown). We also observed that, of the total
CCL23 synthesized by R848-treated neutrophils, ∼15% remains
cell-associated (Figure 3B), indicating that CCL23 is almost
completely released. And in fact, two potent secretagogues,
namely fMLF or TNFα, were found unable to mobilize the
small quote of intracellular CCL23 accumulated in R848-treated
neutrophils (Figure 3B).
Monocytes too were found to release CCL23 in response
to R848 (Figure 3A, right panel), surprisingly at lower levels
(87.1 ± 28.5, n = 11) than neutrophils, but consistent with
the gene expression data (Figure 2A). However, monocytes
incubated with IL-4 for up to 48 h were found to accumulate and
release remarkable levels of CCL23 mRNA and protein (308.6 ±
149.2 pg/ml, n = 4) (left panels in Figure 4A and Figure 4C,
respectively), confirming previous data (Novak et al., 2007).
By contrast, IL-4-treated neutrophils did not express/produce
any CCL23 mRNA and protein (right panels in Figure 4A
and Figure 4C, respectively), even though they accumulated IL-
1ra mRNA (right panel in Figure 4B), as previously described
(Crepaldi et al., 2002). Altogether, data prove that neutrophils
genuinely produce CCL23 in response to R848 but not
to IL-4.
Effect of IFNα on CCL23 Production by
R848-Treated Neutrophils
Given the recently reported capacity of IFNα to potently increase
IL-6 and TNFα mRNA and protein expression in R848-treated
FIGURE 5 | IFNα downregulates the production of CCL23 by
R848-treated neutrophils Neutrophils (5 × 106/ml) were cultured with or
without 1,000U/ml IFNα and/or 5µM R848. After 24 h, supernatants were
collected and subjected to CCL23, CCL2, CCL3, and CCL4 measurement by
ELISA. Data are depicted as mean ± SEM (n = 3–19). Asterisks stand for
significant increases: **P < 0.01, ***P < 0.001, by two-way ANOVA followed
by Bonferroni’s post-test.
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FIGURE 6 | Other agonists, besides R848, trigger the production of
CCL23 by human neutrophils. Neutrophils (5 × 106/ml) were cultured with
or without 5–50µM R837, 5µM R848, 5µM CL075, 0.1–10µg/ml LPS,
1µg/ml Pam3CSK4, 10 ng/ml TNFα, 10 nM fMLF, 10 ng/ml G-CSF, 10 ng/ml
GM-CSF, 500µg/ml β-Glucan, 500µg/ml Curdlan, 100 ng/ml IL-18, and
100 ng/ml IL-33 for 24 h. Then, extracellular supernatants were collected to
evaluate CCL23 (A) and CXCL8 (B) production by ELISA (mean ± SEM,
n = 3–5). Asterisks stand for significant increases as compared to untreated
cells: *P < 0.05,
(Continued)
FIGURE 6 | Continued
**P < 0.01, ***P < 0.001, by Student’s t-test. (C) Neutrophils (5 × 106/ml)
were pretreated for 30min with 10µg/ml adalimumab (ADA) or 10µg/ml
etanercept (ETA), to be subsequently incubated for further 24 h with 5µM
R848. Cell-free supernatants were then collected to evaluate CCL23
production by ELISA (mean ± SEM, n = 3–5). Asterisks stand for significant
inhibition: *P < 0.05, by one-way ANOVA followed by Tukey’s post-test.
neutrophils (Zimmermann et al., 2016), we investigated IFNα-
mediated effects on neutrophil-derived CCL23 and other CCR1-
binding chemokines. As displayed in Figure 5, we found that,
while IFNα strongly downregulates the production of CCL23
by neutrophils incubated with R848 for 24 h, it significantly
upregulates that of CCL2, but does not influence CCL3 and CCL4
release. Interestingly, Figure 5 also illustrates that the amounts
of CCL3 and CCL4 released by R848-stimulated neutrophils are
higher than those of CCL2 and CCL23, in accordance with the
gene expression data (Figure 2). Taken together, data provide
evidence that IFNα negatively modulates CCL23, but not CCL2,
CCL3, and CCL4 production by R848-treated neutrophils.
Other TLR Agonists, as well as TNFα,
Trigger the Production of CCL23 by Human
Neutrophils
In a final series of experiments, we investigated whether other
agonists could induce the production of CCL23 by human
neutrophils. We found that, in addition to R848 (the most
potent one), also 5µM CL075 (another ligand for TLR8),
1µg/ml Pam3CSK4 (a ligand for TLR2), 10µg/ml ultrapure
LPS (a ligand for TLR4), and 10 ng/ml TNFα promoted the
production of remarkable amounts of CCL23 by neutrophils
(respectively, 108.6 ± 59.3, 61.8 ± 13.2, 88.8 ± 1.3, and 65.1
± 28.2 pg/ml, n = 3–5) (Figure 6A). By contrast, 5–50 µM
R837 (a ligand for TLR7), 500µg/ml β-glucan and 500 µg/ml
curdlan (both ligands for Dectin-1), 10 nM fMLF, 10 ng/ml GM-
CSF, and 1,000U/ml G-CSF, all failed to trigger any extracellular
CCL23 production by neutrophils (Figure 6A), albeit able to
stimulate the production of CXCL8 (Figure 6B). Finally, 100
ng/ml IL-18 and IL-33, two cytokines having potential roles
in Th2-responses, resulted unable to induce CCL23 production
in both human neutrophils (Figure 6A) and CD14+-monocytes
(data not shown). IL-18 and IL-33 also did not modulate the
levels of CCL23 produced by R848-treated neutrophils (data not
shown).
Given that R848-treated neutrophils are known to produce
elevated amounts of TNFα (Zimmermann et al., 2015), we
then investigated whether CCL23 production could be amplified
by endogenous TNFα, as occurring in the case of IL-6
(Zimmermann et al., 2015). This was found to be the case, as
adalimumab or etanercept, two potent TNFα-neutralizing drugs
(Tracey et al., 2008), diminished the detection of extracellular
CCL23 in supernatants from neutrophils treated with R848 for
24 h by, respectively, 44.7 ± 5.5% (n = 3) and 45.7 ± 11.4%
(n = 3) (Figure 6C). Altogether, data uncover that neutrophils
produce CCL23 in response to discrete stimuli. Data also
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demonstrate that, at least in the case of R848-treated neutrophils,
CCL23 production is amplified via endogenous TNFα.
DISCUSSION
Neutrophils are among the first cell types that infiltrate
inflammatory sites. As such, they may play an important role
in coordinating the subsequent recruitment of other leukocytes
via the generation of a variety of chemoattractants, including
chemokines (Tecchio and Cassatella, 2016). Among the latter
molecules, neutrophils have been already shown to represent
sources of some CCR1-binding chemokines, namely CCL3 and
CCL4 (Kasama et al., 1994; Scapini et al., 2000), known to act
on monocytes, DCs and resting T lymphocytes (Patel et al., 1997;
Nardelli et al., 1999; Viola and Luster, 2008).
In this study, we show that human neutrophils are able to
produce another CCR1-binding chemokine, namely CCL23, in
response to ligands for TLR2 (Pam3CSK4), TLR4 (LPS), and
much more efficiently, TLR8 (R848 and CL075). By contrast,
a variety of inflammatory mediators previously identified as
being effective stimuli for the production of chemokines by
neutrophils, for instance G-CSF, GM-CSF, and fMLF (Cassatella,
1999), failed to trigger CCL23 production. Other CCR1-binding
chemokines, including CCL5, CCL7, CCL13, CCL14, CCL15,
and CCL16 were found as not induced in neutrophils, at
least after R848-treatment. Surprisingly, the amounts of CCL23
produced by neutrophils incubated with R848 for 24 h were
comparable to those made by the same number of autologous
R848-treated monocytes. This finding is quite unusual because,
on a per cell basis, activated monocytes usually produce
higher cytokine/chemokine levels than autologous neutrophils
(Cassatella, 1999; Dale et al., 2008), although some other
exceptions exist, for instance CCL19/MIP3β (Scapini et al.,
2001). Whatever the case is, our findings exclude that the
observed CCL23 production by R848-treated neutrophils derives
from potential contaminating monocytes. Moreover, they also
imply that appropriately activated neutrophils may represent
major sources of CCL23, even in consideration of the fact
that, during bacterial or viral infections, neutrophils often
outnumber mononuclear leukocytes by one to two orders of
magnitude.
We also report that, differently from autologous monocytes
(Novak et al., 2007), neutrophils do not produce CCL23 upon
incubation with IL-4, a Th2 cytokine, even though they promptly
accumulate IL-1ra mRNA (Re et al., 1993; Crepaldi et al., 2002).
Although we do not have a formal molecular explanation for the
inability of IL-4-treated neutrophils to express CCL23 mRNA
yet, our preliminary genome-wide map of both histone H3
monomethylated at K4 (H3K4me1, which is associated with
active or poised genomic regulatory elements) (Smale et al.,
2014) and PU.1 (an Ets-family transcription factor marking
the majority of regulatory elements in myeloid cells) (Smale
et al., 2014) would reveal that neutrophils contain only one
regulatory region at the CCL23 locus (1 kb upstream from CCL23
TSS), while monocytes contain two ones (1 and 25 kb upstream
from CCL23 TSS). Such a different chromatin conformation
might be responsible for the differential ability of neutrophils
and monocytes to express CCL23 mRNA in response to IL-
4 stimulation, as the “closed” chromatin conformation in
neutrophils would, in fact, prevent the binding of IL-4-activated
transcription factor(s) to it, and consequently the transcription
of CCL23 mRNA. Interestingly, other Th2 cytokines, namely
IL-18 and IL-33, were found unable to trigger the production
of CCL23 by human neutrophils. Therefore, along with the
findings on IL-4, our data would exclude the generation of
neutrophils conditioned by Th2 cytokines and associated to Th2-
microenvironment.
According to previous findings (Youn et al., 1998), CCL23
may exist in multiple forms arising from both alternative splicing
and post-translational processing. CCL23 cDNA encodes, in
fact, a signal sequence of 21 aa followed by either a 99
aa (also known as CKβ8) or 116 aa (CKβ8-1) mature
proteins, which both represent putative ligands for CCR1
(Youn et al., 1998). In such regard, our preliminary RT-qPCR
experiments would indicate that R848-stimulated neutrophils
express both mRNA isoforms, while monocytes express only
CKβ8-1 mRNA (NT, FA, and MAC, unpublished results).
As mentioned, eosinophils have been shown to express and
release CCL23, and, similarly to R848-activated neutrophils, they
accumulate both mRNA isoforms of CCL23 (Matsumoto et al.,
2011). In any case, we exclude that the two CCL23 mRNAs
detected in neutrophils derive from potential contaminating
eosinophils, as our neutrophil purification method reduces
eosinophil contamination below 0.1% (Calzetti et al., 2017).
Moreover, GM-CSF, which triggers the release of CCL23 by
eosinophils (Matsumoto et al., 2011), resulted ineffective in
neutrophils.
In this work, we also report that the production of
CCR1-binding chemokines by R848-activated neutrophils is
differentially modulated by IFNα. In fact, while production
of CCL3 and CCL4 was not affected by the addition of
IFNα to neutrophils, that of CCL23 was strongly inhibited. By
contrast, CCL2 production was strongly enhanced in neutrophils
incubated with R848 in the presence of IFNα, similarly to
what previously observed in neutrophils treated with IFNγ
plus LPS (Yoshimura and Takahashi, 2007). Together, our data
therefore reinforce the notion that type I interferons do not
act as mere enhancers of inflammatory gene expression, but
represent instead fine tuners regulating the transcription of
a variety of mediators (González-Navajas et al., 2012; McNab
et al., 2015), including neutrophil-derived chemokines. Given the
potent effect of TLR8 agonists in inducing neutrophil-derived
CCL23, and its negative regulation by IFNα, data also contribute
to extend our knowledge on the complex role of neutrophils
to both host defense and disease in response to viral infections
(Tamassia and Cassatella, 2013; Galani and Andreakos, 2015).
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